Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colonic Neoplasms | 98 | 2024 | 2532 | 13.020 |
Why?
|
Colorectal Neoplasms | 231 | 2025 | 6961 | 11.740 |
Why?
|
Fluorouracil | 50 | 2024 | 1648 | 3.230 |
Why?
|
Chemotherapy, Adjuvant | 55 | 2024 | 3546 | 3.200 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 90 | 2024 | 11859 | 3.030 |
Why?
|
Rectal Neoplasms | 22 | 2024 | 1183 | 2.780 |
Why?
|
Exercise | 35 | 2025 | 5939 | 2.720 |
Why?
|
Neoplasm Staging | 94 | 2024 | 11200 | 2.680 |
Why?
|
Neoplasm Recurrence, Local | 49 | 2024 | 9378 | 2.450 |
Why?
|
Microsatellite Instability | 45 | 2024 | 726 | 2.340 |
Why?
|
Leucovorin | 35 | 2024 | 643 | 2.340 |
Why?
|
Diet | 37 | 2024 | 8087 | 1.990 |
Why?
|
Disease-Free Survival | 53 | 2024 | 6840 | 1.870 |
Why?
|
Organoplatinum Compounds | 24 | 2024 | 407 | 1.730 |
Why?
|
Cyclooxygenase 2 Inhibitors | 5 | 2024 | 319 | 1.720 |
Why?
|
Adenocarcinoma | 31 | 2024 | 6363 | 1.530 |
Why?
|
Life Style | 17 | 2022 | 3928 | 1.480 |
Why?
|
Camptothecin | 24 | 2022 | 598 | 1.390 |
Why?
|
Prospective Studies | 134 | 2024 | 54812 | 1.360 |
Why?
|
Peripheral Nervous System Diseases | 7 | 2024 | 713 | 1.350 |
Why?
|
Gastrointestinal Neoplasms | 8 | 2023 | 958 | 1.310 |
Why?
|
CpG Islands | 27 | 2024 | 1207 | 1.260 |
Why?
|
Liver Neoplasms | 22 | 2024 | 4352 | 1.250 |
Why?
|
Aged | 236 | 2025 | 171219 | 1.210 |
Why?
|
Feeding Behavior | 16 | 2021 | 3209 | 1.200 |
Why?
|
Body Mass Index | 35 | 2024 | 13046 | 1.200 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 24 | 2024 | 904 | 1.160 |
Why?
|
Middle Aged | 249 | 2025 | 223083 | 1.140 |
Why?
|
Leukemia | 4 | 2023 | 1522 | 1.110 |
Why?
|
Proportional Hazards Models | 64 | 2024 | 12529 | 1.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 38 | 2024 | 2054 | 1.080 |
Why?
|
Motor Activity | 12 | 2015 | 2711 | 1.080 |
Why?
|
Carcinoma, Hepatocellular | 17 | 2024 | 2327 | 1.060 |
Why?
|
Humans | 424 | 2025 | 766117 | 1.050 |
Why?
|
Diet, Vegetarian | 3 | 2025 | 181 | 1.040 |
Why?
|
Male | 284 | 2025 | 363935 | 1.020 |
Why?
|
Female | 299 | 2025 | 396233 | 1.010 |
Why?
|
Prognosis | 85 | 2024 | 29912 | 0.990 |
Why?
|
Exercise Therapy | 10 | 2025 | 938 | 0.960 |
Why?
|
Metformin | 2 | 2024 | 903 | 0.940 |
Why?
|
Survivors | 12 | 2023 | 2375 | 0.930 |
Why?
|
Dietary Sucrose | 3 | 2018 | 241 | 0.880 |
Why?
|
Adiposity | 10 | 2022 | 1892 | 0.850 |
Why?
|
Deoxycytidine | 11 | 2019 | 886 | 0.840 |
Why?
|
Medical Oncology | 17 | 2024 | 2339 | 0.840 |
Why?
|
Follow-Up Studies | 77 | 2024 | 39243 | 0.840 |
Why?
|
Antineoplastic Agents | 33 | 2025 | 13635 | 0.830 |
Why?
|
DNA Methylation | 37 | 2024 | 4425 | 0.820 |
Why?
|
Body Composition | 11 | 2023 | 2441 | 0.810 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 13 | 2022 | 1105 | 0.810 |
Why?
|
Survival Rate | 41 | 2022 | 12827 | 0.790 |
Why?
|
Fusobacterium nucleatum | 6 | 2024 | 176 | 0.750 |
Why?
|
ras Proteins | 21 | 2014 | 1054 | 0.750 |
Why?
|
Resistance Training | 5 | 2024 | 197 | 0.740 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 3 | 2020 | 207 | 0.740 |
Why?
|
Hyperinsulinism | 5 | 2023 | 402 | 0.730 |
Why?
|
Cohort Studies | 66 | 2024 | 41684 | 0.720 |
Why?
|
Stomach Neoplasms | 11 | 2024 | 1471 | 0.720 |
Why?
|
Intra-Abdominal Fat | 3 | 2021 | 624 | 0.710 |
Why?
|
Combined Modality Therapy | 20 | 2024 | 8525 | 0.690 |
Why?
|
Survival Analysis | 34 | 2021 | 10087 | 0.690 |
Why?
|
Secondary Prevention | 3 | 2021 | 1470 | 0.690 |
Why?
|
Adiponectin | 4 | 2024 | 1120 | 0.670 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 4 | 2020 | 416 | 0.670 |
Why?
|
Adult | 161 | 2024 | 223139 | 0.660 |
Why?
|
C-Reactive Protein | 5 | 2024 | 3853 | 0.660 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2023 | 278 | 0.660 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2020 | 91 | 0.650 |
Why?
|
Neoplasm Metastasis | 18 | 2025 | 4887 | 0.610 |
Why?
|
Neoplasms | 24 | 2025 | 22344 | 0.600 |
Why?
|
Cyclooxygenase 2 | 9 | 2020 | 595 | 0.600 |
Why?
|
Phosphatidylinositol 3-Kinases | 21 | 2021 | 2877 | 0.600 |
Why?
|
Quinazolines | 10 | 2013 | 1366 | 0.590 |
Why?
|
Long Interspersed Nucleotide Elements | 15 | 2020 | 332 | 0.580 |
Why?
|
Mutation | 52 | 2024 | 30209 | 0.570 |
Why?
|
Seafood | 2 | 2018 | 395 | 0.570 |
Why?
|
Kaplan-Meier Estimate | 30 | 2020 | 6506 | 0.570 |
Why?
|
Inflammation | 5 | 2024 | 10860 | 0.570 |
Why?
|
Risk Factors | 76 | 2024 | 74857 | 0.560 |
Why?
|
Aged, 80 and over | 69 | 2024 | 59515 | 0.560 |
Why?
|
Pancreatic Neoplasms | 15 | 2024 | 5454 | 0.540 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 26 | 2024 | 1765 | 0.540 |
Why?
|
Sarcopenia | 5 | 2020 | 378 | 0.540 |
Why?
|
Fatty Acids, Omega-3 | 4 | 2020 | 1399 | 0.540 |
Why?
|
Muscle, Skeletal | 8 | 2023 | 4959 | 0.530 |
Why?
|
Nutrition Policy | 2 | 2018 | 467 | 0.530 |
Why?
|
Vitamins | 7 | 2024 | 1631 | 0.530 |
Why?
|
Clinical Trials, Phase III as Topic | 9 | 2021 | 878 | 0.520 |
Why?
|
Tumor Microenvironment | 13 | 2022 | 3942 | 0.520 |
Why?
|
Obesity | 19 | 2020 | 13085 | 0.520 |
Why?
|
C-Peptide | 7 | 2024 | 443 | 0.520 |
Why?
|
Dietary Supplements | 10 | 2024 | 3427 | 0.510 |
Why?
|
Carcinoma, Signet Ring Cell | 5 | 2018 | 80 | 0.510 |
Why?
|
Sweetening Agents | 2 | 2018 | 291 | 0.510 |
Why?
|
Colonic Polyps | 4 | 2022 | 557 | 0.500 |
Why?
|
Coffee | 5 | 2022 | 593 | 0.490 |
Why?
|
Dietary Fats | 3 | 2022 | 2003 | 0.490 |
Why?
|
Geriatric Assessment | 2 | 2013 | 1422 | 0.480 |
Why?
|
Insulin-Like Growth Factor I | 4 | 2020 | 1935 | 0.480 |
Why?
|
Esophageal Neoplasms | 7 | 2024 | 1659 | 0.470 |
Why?
|
United States | 76 | 2025 | 72920 | 0.470 |
Why?
|
Population Surveillance | 4 | 2021 | 2596 | 0.460 |
Why?
|
Glycemic Index | 3 | 2019 | 400 | 0.460 |
Why?
|
Fishes | 1 | 2018 | 607 | 0.460 |
Why?
|
Data Collection | 3 | 2024 | 3318 | 0.460 |
Why?
|
Aspirin | 10 | 2024 | 3135 | 0.460 |
Why?
|
Meat Products | 2 | 2019 | 97 | 0.460 |
Why?
|
Body Weight | 5 | 2024 | 4626 | 0.460 |
Why?
|
Anus Neoplasms | 3 | 2024 | 336 | 0.440 |
Why?
|
Proto-Oncogene Proteins | 19 | 2014 | 4521 | 0.440 |
Why?
|
Energy Metabolism | 5 | 2016 | 2894 | 0.430 |
Why?
|
Antimetabolites, Antineoplastic | 5 | 2019 | 646 | 0.430 |
Why?
|
Physical Exertion | 2 | 2006 | 666 | 0.430 |
Why?
|
Patient Compliance | 4 | 2024 | 2694 | 0.430 |
Why?
|
Neoadjuvant Therapy | 14 | 2024 | 2897 | 0.430 |
Why?
|
Vitamin D | 11 | 2023 | 3272 | 0.420 |
Why?
|
Adenoma | 5 | 2022 | 2155 | 0.410 |
Why?
|
Dairy Products | 3 | 2021 | 490 | 0.410 |
Why?
|
Neuroendocrine Tumors | 6 | 2013 | 657 | 0.400 |
Why?
|
Adenocarcinoma, Mucinous | 5 | 2019 | 521 | 0.400 |
Why?
|
Randomized Controlled Trials as Topic | 25 | 2022 | 10380 | 0.400 |
Why?
|
Lymphatic Metastasis | 8 | 2021 | 2890 | 0.390 |
Why?
|
Interleukin-6 | 6 | 2024 | 3227 | 0.380 |
Why?
|
Weight Loss | 4 | 2024 | 2711 | 0.370 |
Why?
|
Drug Administration Schedule | 13 | 2021 | 4853 | 0.370 |
Why?
|
Calcium, Dietary | 3 | 2019 | 527 | 0.370 |
Why?
|
Colectomy | 7 | 2020 | 697 | 0.370 |
Why?
|
Cardiovascular Diseases | 5 | 2022 | 15647 | 0.360 |
Why?
|
Insulin | 9 | 2019 | 6604 | 0.360 |
Why?
|
Esophagogastric Junction | 5 | 2024 | 350 | 0.360 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 748 | 0.350 |
Why?
|
Antibodies, Monoclonal | 14 | 2014 | 9237 | 0.350 |
Why?
|
Blood Glucose | 3 | 2017 | 6421 | 0.350 |
Why?
|
Breast Neoplasms | 6 | 2024 | 21074 | 0.340 |
Why?
|
Meat | 1 | 2013 | 588 | 0.340 |
Why?
|
California | 6 | 2020 | 1435 | 0.340 |
Why?
|
Multivariate Analysis | 18 | 2021 | 12061 | 0.330 |
Why?
|
Risk Reduction Behavior | 2 | 2019 | 1121 | 0.330 |
Why?
|
Carcinoma | 4 | 2017 | 2313 | 0.320 |
Why?
|
Appendiceal Neoplasms | 2 | 2023 | 155 | 0.320 |
Why?
|
Overweight | 5 | 2016 | 2444 | 0.320 |
Why?
|
Recurrence | 7 | 2023 | 8494 | 0.320 |
Why?
|
Treatment Outcome | 50 | 2025 | 65219 | 0.320 |
Why?
|
Somatomedins | 2 | 2008 | 178 | 0.310 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 7424 | 0.310 |
Why?
|
Gastroenterology | 1 | 2015 | 593 | 0.300 |
Why?
|
Digestive System Surgical Procedures | 2 | 2004 | 584 | 0.300 |
Why?
|
Yoga | 2 | 2022 | 277 | 0.300 |
Why?
|
Nuts | 3 | 2019 | 265 | 0.300 |
Why?
|
Anal Canal | 4 | 2023 | 376 | 0.300 |
Why?
|
Beverages | 4 | 2022 | 819 | 0.290 |
Why?
|
Health Behavior | 3 | 2015 | 2649 | 0.290 |
Why?
|
Dietary Fiber | 4 | 2019 | 767 | 0.290 |
Why?
|
Cisplatin | 6 | 2017 | 1654 | 0.290 |
Why?
|
Risk Assessment | 25 | 2024 | 24276 | 0.290 |
Why?
|
Age Factors | 13 | 2024 | 18386 | 0.290 |
Why?
|
beta Catenin | 8 | 2020 | 1047 | 0.270 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2332 | 0.270 |
Why?
|
Weight Gain | 1 | 2016 | 2356 | 0.260 |
Why?
|
Quality of Life | 14 | 2025 | 13468 | 0.260 |
Why?
|
Genes, ras | 4 | 2020 | 656 | 0.260 |
Why?
|
Confidence Intervals | 4 | 2021 | 2915 | 0.260 |
Why?
|
Tomography, X-Ray Computed | 17 | 2023 | 20700 | 0.260 |
Why?
|
Calcifediol | 2 | 2019 | 156 | 0.260 |
Why?
|
Receptors, Calcium-Sensing | 2 | 2017 | 320 | 0.250 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2007 | 307 | 0.250 |
Why?
|
Radiation Tolerance | 2 | 2018 | 475 | 0.250 |
Why?
|
Colostomy | 2 | 2018 | 107 | 0.250 |
Why?
|
Energy Intake | 4 | 2018 | 2141 | 0.250 |
Why?
|
Recreation | 1 | 2006 | 124 | 0.250 |
Why?
|
Insulin Receptor Substrate Proteins | 2 | 2019 | 558 | 0.250 |
Why?
|
T-Lymphocyte Subsets | 3 | 2021 | 1814 | 0.250 |
Why?
|
Risk | 9 | 2021 | 9599 | 0.250 |
Why?
|
Gallbladder Neoplasms | 1 | 2007 | 190 | 0.250 |
Why?
|
Colon | 5 | 2020 | 1797 | 0.240 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2007 | 1777 | 0.240 |
Why?
|
Comorbidity | 9 | 2022 | 10579 | 0.230 |
Why?
|
Incidence | 21 | 2024 | 21513 | 0.230 |
Why?
|
Hypoglycemic Agents | 3 | 2024 | 3107 | 0.230 |
Why?
|
Radiosurgery | 2 | 2024 | 1328 | 0.230 |
Why?
|
Dacarbazine | 4 | 2013 | 552 | 0.230 |
Why?
|
Gene Expression Regulation, Neoplastic | 14 | 2018 | 8612 | 0.230 |
Why?
|
Hyperglycemia | 1 | 2013 | 1389 | 0.230 |
Why?
|
Pentoxifylline | 1 | 2023 | 53 | 0.220 |
Why?
|
Stomatitis, Aphthous | 1 | 2023 | 51 | 0.210 |
Why?
|
Bacteroides fragilis | 1 | 2024 | 250 | 0.210 |
Why?
|
Behcet Syndrome | 1 | 2023 | 86 | 0.200 |
Why?
|
Cause of Death | 7 | 2022 | 3715 | 0.200 |
Why?
|
Odds Ratio | 13 | 2018 | 9657 | 0.200 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 90 | 0.200 |
Why?
|
Bilirubin | 1 | 2004 | 439 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4049 | 0.200 |
Why?
|
Angiogenesis Inhibitors | 5 | 2017 | 2046 | 0.200 |
Why?
|
Carcinoid Tumor | 3 | 2013 | 225 | 0.190 |
Why?
|
Cholecalciferol | 2 | 2019 | 550 | 0.190 |
Why?
|
Keloid | 1 | 2022 | 55 | 0.190 |
Why?
|
Cholangiocarcinoma | 1 | 2007 | 577 | 0.190 |
Why?
|
Fruit | 2 | 2025 | 1167 | 0.190 |
Why?
|
Bile Duct Neoplasms | 1 | 2007 | 624 | 0.190 |
Why?
|
Vegetables | 2 | 2025 | 1200 | 0.190 |
Why?
|
Creatine | 1 | 2023 | 424 | 0.190 |
Why?
|
Retrospective Studies | 21 | 2024 | 81565 | 0.190 |
Why?
|
Digestive System Neoplasms | 1 | 2021 | 82 | 0.190 |
Why?
|
Hand Strength | 1 | 2024 | 464 | 0.180 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2022 | 135 | 0.180 |
Why?
|
Sirolimus | 4 | 2013 | 1541 | 0.180 |
Why?
|
Smoking | 6 | 2022 | 9082 | 0.180 |
Why?
|
Monosaccharides | 1 | 2021 | 64 | 0.180 |
Why?
|
Alkylating Agents | 1 | 2021 | 133 | 0.180 |
Why?
|
Young Adult | 19 | 2023 | 59868 | 0.180 |
Why?
|
Molecular Epidemiology | 4 | 2019 | 472 | 0.180 |
Why?
|
Fusobacterium Infections | 1 | 2021 | 54 | 0.180 |
Why?
|
Laxatives | 1 | 2021 | 94 | 0.180 |
Why?
|
Societies, Medical | 3 | 2018 | 3955 | 0.170 |
Why?
|
Attitude to Health | 2 | 2019 | 2020 | 0.170 |
Why?
|
Adenomatous Polyps | 1 | 2021 | 109 | 0.170 |
Why?
|
Health Personnel | 5 | 2024 | 3387 | 0.170 |
Why?
|
Nomograms | 1 | 2022 | 235 | 0.170 |
Why?
|
Alcohol Drinking | 4 | 2018 | 4044 | 0.170 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2006 | 2425 | 0.170 |
Why?
|
Flavonoids | 1 | 2023 | 446 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2021 | 2271 | 0.170 |
Why?
|
Research Subjects | 1 | 2021 | 248 | 0.160 |
Why?
|
Vitamin D-Binding Protein | 1 | 2020 | 129 | 0.160 |
Why?
|
Chemoprevention | 1 | 2022 | 327 | 0.160 |
Why?
|
Sex Factors | 7 | 2024 | 10614 | 0.160 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1621 | 0.160 |
Why?
|
Immunohistochemistry | 15 | 2021 | 11035 | 0.160 |
Why?
|
Gastrointestinal Motility | 1 | 2021 | 235 | 0.160 |
Why?
|
Autophagy | 2 | 2020 | 1349 | 0.160 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2021 | 249 | 0.160 |
Why?
|
Endpoint Determination | 2 | 2020 | 591 | 0.160 |
Why?
|
Caffeine | 3 | 2020 | 702 | 0.160 |
Why?
|
Granulocytes | 1 | 2021 | 548 | 0.160 |
Why?
|
Bifidobacteriales Infections | 1 | 2018 | 10 | 0.160 |
Why?
|
Paraffin Embedding | 1 | 2020 | 302 | 0.160 |
Why?
|
Tissue Fixation | 1 | 2020 | 245 | 0.160 |
Why?
|
Genes, DCC | 2 | 2001 | 10 | 0.150 |
Why?
|
Maximum Tolerated Dose | 3 | 2012 | 895 | 0.150 |
Why?
|
Natural Killer T-Cells | 1 | 2021 | 319 | 0.150 |
Why?
|
Formaldehyde | 1 | 2020 | 360 | 0.150 |
Why?
|
Adipose Tissue | 5 | 2023 | 3315 | 0.150 |
Why?
|
Escherichia coli Infections | 1 | 2022 | 519 | 0.150 |
Why?
|
Phenylurea Compounds | 3 | 2024 | 536 | 0.150 |
Why?
|
Muscular Disorders, Atrophic | 1 | 2018 | 24 | 0.150 |
Why?
|
Nutrition Surveys | 1 | 2005 | 1735 | 0.150 |
Why?
|
Bifidobacterium | 1 | 2018 | 99 | 0.150 |
Why?
|
American Cancer Society | 2 | 2022 | 69 | 0.150 |
Why?
|
Diet, Carbohydrate-Restricted | 1 | 2021 | 263 | 0.150 |
Why?
|
Age of Onset | 2 | 2024 | 3344 | 0.150 |
Why?
|
Up-Regulation | 6 | 2019 | 4133 | 0.140 |
Why?
|
Case-Control Studies | 9 | 2024 | 22228 | 0.140 |
Why?
|
DNA, Neoplasm | 8 | 2023 | 1739 | 0.140 |
Why?
|
Early Termination of Clinical Trials | 1 | 2017 | 70 | 0.140 |
Why?
|
Lymph Nodes | 3 | 2021 | 3456 | 0.140 |
Why?
|
Databases, Factual | 8 | 2021 | 8062 | 0.140 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2019 | 266 | 0.140 |
Why?
|
Metabolome | 2 | 2024 | 1005 | 0.140 |
Why?
|
Intestinal Neoplasms | 1 | 2019 | 314 | 0.140 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2593 | 0.140 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 706 | 0.130 |
Why?
|
Consensus | 2 | 2024 | 3202 | 0.130 |
Why?
|
Disease Progression | 5 | 2019 | 13616 | 0.130 |
Why?
|
Chimerin Proteins | 1 | 2016 | 6 | 0.130 |
Why?
|
Self Care | 2 | 2019 | 800 | 0.130 |
Why?
|
Fish Oils | 2 | 2019 | 483 | 0.130 |
Why?
|
Administration, Oral | 6 | 2016 | 4016 | 0.130 |
Why?
|
Fructose | 2 | 2022 | 285 | 0.130 |
Why?
|
Critical Pathways | 1 | 2020 | 475 | 0.130 |
Why?
|
Nurses | 6 | 2020 | 2503 | 0.130 |
Why?
|
Neoplasm Proteins | 3 | 2020 | 3594 | 0.130 |
Why?
|
DNA Repair Enzymes | 2 | 2008 | 342 | 0.130 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2017 | 388 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2003 | 1318 | 0.130 |
Why?
|
Continuity of Patient Care | 1 | 2003 | 1075 | 0.130 |
Why?
|
SEER Program | 5 | 2021 | 1443 | 0.130 |
Why?
|
Respiratory Tract Diseases | 1 | 2021 | 744 | 0.130 |
Why?
|
Pyridines | 3 | 2014 | 2889 | 0.130 |
Why?
|
Epidemiologic Studies | 3 | 2016 | 677 | 0.130 |
Why?
|
Nerve Growth Factors | 1 | 1999 | 564 | 0.130 |
Why?
|
Medicare | 4 | 2012 | 6820 | 0.130 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 8038 | 0.130 |
Why?
|
Pancreaticoduodenectomy | 1 | 2019 | 515 | 0.130 |
Why?
|
Radiopharmaceuticals | 3 | 2021 | 2702 | 0.130 |
Why?
|
Telomere | 1 | 2022 | 941 | 0.120 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2824 | 0.120 |
Why?
|
Phenotype | 13 | 2023 | 16716 | 0.120 |
Why?
|
Positron-Emission Tomography | 3 | 2021 | 6545 | 0.120 |
Why?
|
Forecasting | 2 | 2022 | 2936 | 0.120 |
Why?
|
Folic Acid | 2 | 2015 | 1337 | 0.120 |
Why?
|
Tertiary Prevention | 1 | 2015 | 8 | 0.120 |
Why?
|
DNA Copy Number Variations | 1 | 2024 | 2045 | 0.120 |
Why?
|
Genes, p16 | 2 | 2017 | 157 | 0.120 |
Why?
|
Adipokines | 1 | 2017 | 308 | 0.120 |
Why?
|
Neoplasm Invasiveness | 3 | 2020 | 3602 | 0.120 |
Why?
|
Breast Feeding | 1 | 2023 | 1363 | 0.120 |
Why?
|
Metabolomics | 1 | 2024 | 1667 | 0.120 |
Why?
|
Folic Acid Deficiency | 1 | 2015 | 117 | 0.120 |
Why?
|
Tooth Loss | 1 | 2016 | 198 | 0.120 |
Why?
|
Treatment Failure | 1 | 2021 | 2653 | 0.120 |
Why?
|
Dideoxynucleosides | 1 | 2015 | 135 | 0.120 |
Why?
|
Registries | 4 | 2020 | 8347 | 0.120 |
Why?
|
Melanoma | 2 | 2023 | 5695 | 0.120 |
Why?
|
Infusions, Intravenous | 3 | 2009 | 2227 | 0.120 |
Why?
|
Multicenter Studies as Topic | 4 | 2022 | 1729 | 0.110 |
Why?
|
Lymphocyte Count | 4 | 2020 | 791 | 0.110 |
Why?
|
Calcium Signaling | 1 | 2019 | 734 | 0.110 |
Why?
|
Precancerous Conditions | 1 | 2021 | 975 | 0.110 |
Why?
|
Neurotoxicity Syndromes | 1 | 2018 | 302 | 0.110 |
Why?
|
Loss of Heterozygosity | 4 | 2009 | 663 | 0.110 |
Why?
|
Predictive Value of Tests | 9 | 2021 | 15403 | 0.110 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2016 | 347 | 0.110 |
Why?
|
Health Care Surveys | 1 | 2021 | 2426 | 0.110 |
Why?
|
Antibodies, Viral | 2 | 2023 | 3214 | 0.110 |
Why?
|
Prostatic Neoplasms | 2 | 2021 | 11094 | 0.110 |
Why?
|
Pathology, Molecular | 2 | 2017 | 329 | 0.110 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2023 | 12235 | 0.110 |
Why?
|
Hepatitis C | 1 | 2024 | 1596 | 0.110 |
Why?
|
Quality Assurance, Health Care | 1 | 2024 | 2171 | 0.110 |
Why?
|
Pilot Projects | 7 | 2023 | 8724 | 0.110 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2009 | 373 | 0.110 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2015 | 198 | 0.110 |
Why?
|
DNA, Bacterial | 1 | 2018 | 1476 | 0.110 |
Why?
|
Adolescent | 14 | 2023 | 88819 | 0.110 |
Why?
|
Hospitals | 2 | 2004 | 3887 | 0.110 |
Why?
|
Muscles | 1 | 2018 | 1576 | 0.110 |
Why?
|
Intestine, Small | 1 | 2019 | 1216 | 0.110 |
Why?
|
Periodontal Diseases | 1 | 2016 | 453 | 0.100 |
Why?
|
Qualitative Research | 1 | 2024 | 3138 | 0.100 |
Why?
|
Vitamin D Deficiency | 2 | 2013 | 1348 | 0.100 |
Why?
|
Forkhead Transcription Factors | 1 | 2020 | 1623 | 0.100 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 163 | 0.100 |
Why?
|
Walking | 1 | 2020 | 1198 | 0.100 |
Why?
|
Ontario | 1 | 2013 | 403 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 2007 | 0.100 |
Why?
|
Cholesterol | 1 | 2022 | 2902 | 0.100 |
Why?
|
Television | 1 | 2015 | 409 | 0.100 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1609 | 0.100 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3249 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 5 | 2017 | 2795 | 0.100 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2025 | 299 | 0.100 |
Why?
|
Diet Records | 3 | 2020 | 425 | 0.100 |
Why?
|
Adolescent Behavior | 1 | 2021 | 1184 | 0.100 |
Why?
|
Sarcoma | 1 | 2023 | 1801 | 0.100 |
Why?
|
Codon | 1 | 2014 | 599 | 0.100 |
Why?
|
T-Lymphocytes | 3 | 2022 | 10260 | 0.100 |
Why?
|
Income | 1 | 2021 | 1874 | 0.100 |
Why?
|
Insurance Claim Review | 1 | 2016 | 744 | 0.100 |
Why?
|
Germ-Line Mutation | 4 | 2018 | 1885 | 0.100 |
Why?
|
Biomedical Research | 3 | 2019 | 3458 | 0.100 |
Why?
|
Diet, Mediterranean | 2 | 2019 | 746 | 0.100 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 9527 | 0.100 |
Why?
|
Caregivers | 1 | 2024 | 2304 | 0.100 |
Why?
|
Brain Neoplasms | 3 | 2021 | 9065 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1637 | 0.100 |
Why?
|
Residence Characteristics | 1 | 2021 | 2116 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 5 | 2023 | 5695 | 0.090 |
Why?
|
Vitamin B 6 | 1 | 2013 | 237 | 0.090 |
Why?
|
Time Factors | 12 | 2021 | 40108 | 0.090 |
Why?
|
Monocytes | 1 | 2021 | 2591 | 0.090 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2024 | 1762 | 0.090 |
Why?
|
Logistic Models | 7 | 2024 | 13273 | 0.090 |
Why?
|
Neuroblastoma | 2 | 2001 | 1263 | 0.090 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1404 | 0.090 |
Why?
|
Tegafur | 2 | 2013 | 39 | 0.090 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 2 | 2009 | 82 | 0.090 |
Why?
|
DNA Mismatch Repair | 3 | 2023 | 432 | 0.090 |
Why?
|
Animals | 15 | 2024 | 168800 | 0.090 |
Why?
|
Epigenomics | 2 | 2017 | 959 | 0.090 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2009 | 314 | 0.090 |
Why?
|
Cell Lineage | 1 | 2020 | 2573 | 0.090 |
Why?
|
Interdisciplinary Communication | 2 | 2015 | 931 | 0.090 |
Why?
|
Physical Fitness | 2 | 2013 | 743 | 0.090 |
Why?
|
Vitamin B Complex | 1 | 2013 | 299 | 0.090 |
Why?
|
Dietary Carbohydrates | 2 | 2012 | 896 | 0.090 |
Why?
|
Lymphocytes | 3 | 2020 | 2602 | 0.090 |
Why?
|
Nutritional Status | 2 | 2025 | 1620 | 0.090 |
Why?
|
Diet Therapy | 1 | 2011 | 149 | 0.090 |
Why?
|
bcl-2-Associated X Protein | 1 | 2011 | 282 | 0.090 |
Why?
|
Insulin-Like Growth Factor II | 2 | 2008 | 271 | 0.090 |
Why?
|
Epidemiology | 1 | 2013 | 278 | 0.090 |
Why?
|
MicroRNAs | 2 | 2016 | 3787 | 0.090 |
Why?
|
Enkephalins | 1 | 1990 | 139 | 0.090 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2011 | 305 | 0.090 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4556 | 0.090 |
Why?
|
Gastrectomy | 2 | 2007 | 693 | 0.080 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 429 | 0.080 |
Why?
|
MutS Homolog 2 Protein | 3 | 2017 | 200 | 0.080 |
Why?
|
Intestinal Perforation | 1 | 2012 | 254 | 0.080 |
Why?
|
Genes, bcl-1 | 1 | 2009 | 11 | 0.080 |
Why?
|
Oncogene Protein p21(ras) | 1 | 2009 | 68 | 0.080 |
Why?
|
HLA-DR Antigens | 2 | 2021 | 608 | 0.080 |
Why?
|
Calcium | 2 | 2019 | 5770 | 0.080 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1961 | 0.080 |
Why?
|
Central Nervous System Stimulants | 1 | 2017 | 1167 | 0.080 |
Why?
|
Rectum | 3 | 2019 | 896 | 0.080 |
Why?
|
Insulin Resistance | 2 | 2021 | 3988 | 0.080 |
Why?
|
Nausea | 2 | 2016 | 679 | 0.080 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2009 | 284 | 0.080 |
Why?
|
Waist Circumference | 2 | 2024 | 934 | 0.080 |
Why?
|
Telephone | 1 | 2011 | 627 | 0.070 |
Why?
|
Tea | 2 | 2023 | 289 | 0.070 |
Why?
|
Health Occupations | 2 | 2021 | 226 | 0.070 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2009 | 614 | 0.070 |
Why?
|
Safety | 1 | 2012 | 1157 | 0.070 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 615 | 0.070 |
Why?
|
Pandemics | 3 | 2022 | 8725 | 0.070 |
Why?
|
Biliary Tract Neoplasms | 1 | 2009 | 186 | 0.070 |
Why?
|
Fatigue | 2 | 2025 | 1552 | 0.070 |
Why?
|
Albumins | 2 | 2023 | 578 | 0.070 |
Why?
|
Research Design | 3 | 2020 | 6206 | 0.070 |
Why?
|
Quinolines | 1 | 2013 | 769 | 0.070 |
Why?
|
Subcutaneous Fat | 2 | 2021 | 401 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2024 | 10737 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13483 | 0.070 |
Why?
|
Mass Screening | 1 | 2003 | 5450 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2021 | 2029 | 0.070 |
Why?
|
Models, Statistical | 1 | 2022 | 5089 | 0.070 |
Why?
|
Receptors, Calcitriol | 1 | 2009 | 361 | 0.070 |
Why?
|
Models, Genetic | 1 | 2017 | 3448 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3617 | 0.070 |
Why?
|
Decision Making | 3 | 2020 | 3955 | 0.070 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2010 | 594 | 0.070 |
Why?
|
Standard of Care | 1 | 2011 | 568 | 0.070 |
Why?
|
Testis | 1 | 1990 | 782 | 0.070 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2014 | 1245 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3238 | 0.070 |
Why?
|
Fluorescent Antibody Technique | 2 | 2021 | 2469 | 0.070 |
Why?
|
DNA Modification Methylases | 1 | 2007 | 207 | 0.070 |
Why?
|
Oxonic Acid | 1 | 2006 | 31 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5926 | 0.070 |
Why?
|
Genes | 1 | 1990 | 1824 | 0.070 |
Why?
|
Inflammation Mediators | 1 | 2015 | 1890 | 0.070 |
Why?
|
Immunoenzyme Techniques | 3 | 2015 | 1695 | 0.070 |
Why?
|
RNA-Binding Proteins | 2 | 2012 | 1883 | 0.070 |
Why?
|
Preoperative Care | 3 | 2023 | 2249 | 0.070 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 620 | 0.070 |
Why?
|
Prevalence | 4 | 2023 | 15827 | 0.060 |
Why?
|
Protein Precursors | 1 | 1990 | 1133 | 0.060 |
Why?
|
Tocopherols | 1 | 2005 | 43 | 0.060 |
Why?
|
Membrane Proteins | 2 | 2007 | 7850 | 0.060 |
Why?
|
Endostatins | 1 | 2006 | 167 | 0.060 |
Why?
|
Surgery Department, Hospital | 1 | 2007 | 170 | 0.060 |
Why?
|
DNA Mutational Analysis | 5 | 2017 | 4112 | 0.060 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2009 | 590 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4649 | 0.060 |
Why?
|
Neutrophils | 1 | 2017 | 3771 | 0.060 |
Why?
|
Intention to Treat Analysis | 2 | 2018 | 418 | 0.060 |
Why?
|
Diet Surveys | 2 | 2019 | 1159 | 0.060 |
Why?
|
Watchful Waiting | 2 | 2019 | 492 | 0.060 |
Why?
|
Observation | 1 | 2006 | 310 | 0.060 |
Why?
|
Salvage Therapy | 2 | 2009 | 1273 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 4 | 2017 | 18076 | 0.060 |
Why?
|
Promoter Regions, Genetic | 3 | 2011 | 5784 | 0.060 |
Why?
|
Length of Stay | 2 | 2020 | 6490 | 0.060 |
Why?
|
Biopsy | 3 | 2023 | 6768 | 0.060 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.060 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2004 | 70 | 0.050 |
Why?
|
Levamisole | 1 | 2003 | 36 | 0.050 |
Why?
|
Piperidines | 1 | 2012 | 1664 | 0.050 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 3432 | 0.050 |
Why?
|
Estradiol | 1 | 2010 | 1947 | 0.050 |
Why?
|
Appetite | 1 | 2005 | 247 | 0.050 |
Why?
|
Nucleocapsid | 1 | 2023 | 61 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2020 | 20137 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6612 | 0.050 |
Why?
|
Paclitaxel | 2 | 2023 | 1727 | 0.050 |
Why?
|
Chromosomes, Human, Pair 18 | 3 | 2009 | 247 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1120 | 0.050 |
Why?
|
Health Promotion | 1 | 2015 | 2209 | 0.050 |
Why?
|
Prodrugs | 1 | 2005 | 274 | 0.050 |
Why?
|
Carotenoids | 1 | 2005 | 620 | 0.050 |
Why?
|
Anxiety | 1 | 2017 | 4672 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2022 | 61 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8616 | 0.050 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2006 | 343 | 0.050 |
Why?
|
Nutrition Assessment | 1 | 2005 | 738 | 0.050 |
Why?
|
Genotype | 4 | 2022 | 13028 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 4 | 2014 | 2455 | 0.050 |
Why?
|
Poultry | 1 | 2022 | 79 | 0.050 |
Why?
|
Cell Differentiation | 2 | 2017 | 11642 | 0.050 |
Why?
|
Genetic Testing | 1 | 2015 | 3594 | 0.050 |
Why?
|
Polymerase Chain Reaction | 4 | 2013 | 6059 | 0.050 |
Why?
|
Furosemide | 1 | 2022 | 174 | 0.050 |
Why?
|
Niacinamide | 1 | 2024 | 419 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1611 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5836 | 0.050 |
Why?
|
Inpatients | 1 | 2013 | 2566 | 0.050 |
Why?
|
Escherichia coli | 2 | 2024 | 4210 | 0.050 |
Why?
|
ROC Curve | 2 | 2020 | 3614 | 0.050 |
Why?
|
Indoles | 1 | 2009 | 1833 | 0.050 |
Why?
|
Intention | 1 | 2024 | 346 | 0.040 |
Why?
|
Gene Silencing | 1 | 2007 | 1504 | 0.040 |
Why?
|
Preoperative Period | 1 | 2023 | 565 | 0.040 |
Why?
|
Marital Status | 1 | 2022 | 426 | 0.040 |
Why?
|
Republic of Korea | 2 | 2013 | 591 | 0.040 |
Why?
|
Muscular Atrophy | 1 | 2023 | 335 | 0.040 |
Why?
|
Medical Record Linkage | 2 | 2012 | 286 | 0.040 |
Why?
|
Hematoxylin | 1 | 2020 | 61 | 0.040 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2020 | 70 | 0.040 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2023 | 415 | 0.040 |
Why?
|
Tumor Burden | 2 | 2020 | 1889 | 0.040 |
Why?
|
Withholding Treatment | 2 | 2017 | 619 | 0.040 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1394 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2023 | 384 | 0.040 |
Why?
|
North America | 1 | 2004 | 1287 | 0.040 |
Why?
|
Estrogen Replacement Therapy | 1 | 2006 | 1206 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2004 | 615 | 0.040 |
Why?
|
Poverty Areas | 1 | 2021 | 268 | 0.040 |
Why?
|
Drug Carriers | 1 | 2004 | 701 | 0.040 |
Why?
|
Health Surveys | 3 | 2017 | 4058 | 0.040 |
Why?
|
Liver | 2 | 2019 | 7559 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 634 | 0.040 |
Why?
|
Patient Dropouts | 2 | 2013 | 411 | 0.040 |
Why?
|
Amino Acid Sequence | 3 | 1999 | 13400 | 0.040 |
Why?
|
Homeodomain Proteins | 1 | 2009 | 2430 | 0.040 |
Why?
|
Chromatography, Liquid | 1 | 2023 | 992 | 0.040 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26290 | 0.040 |
Why?
|
Public Health | 1 | 2013 | 2681 | 0.040 |
Why?
|
Cancer Care Facilities | 2 | 2014 | 427 | 0.040 |
Why?
|
Postural Balance | 1 | 2024 | 637 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2017 | 2946 | 0.040 |
Why?
|
Macrophage Activation | 2 | 2020 | 553 | 0.040 |
Why?
|
Sulfonamides | 1 | 2009 | 1980 | 0.040 |
Why?
|
Gene Amplification | 1 | 2024 | 1088 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 686 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2019 | 12426 | 0.040 |
Why?
|
Edema | 1 | 2023 | 763 | 0.040 |
Why?
|
Base Sequence | 4 | 2012 | 12405 | 0.040 |
Why?
|
Obesity, Abdominal | 1 | 2022 | 371 | 0.040 |
Why?
|
Canada | 2 | 2017 | 2120 | 0.040 |
Why?
|
Molecular Sequence Data | 3 | 1999 | 17597 | 0.040 |
Why?
|
Pituitary-Adrenal System | 1 | 2022 | 553 | 0.040 |
Why?
|
Pyrazoles | 1 | 2009 | 2031 | 0.040 |
Why?
|
Trans Fatty Acids | 1 | 2019 | 155 | 0.040 |
Why?
|
Rectus Abdominis | 1 | 2019 | 101 | 0.040 |
Why?
|
Dietary Fats, Unsaturated | 1 | 2019 | 223 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2011 | 5336 | 0.040 |
Why?
|
MAP Kinase Signaling System | 2 | 2018 | 1490 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2020 | 5300 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 787 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3801 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7426 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2010 | 2084 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 2003 | 1613 | 0.040 |
Why?
|
Focus Groups | 1 | 2024 | 1459 | 0.040 |
Why?
|
Epirubicin | 1 | 2017 | 82 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 614 | 0.040 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2022 | 702 | 0.040 |
Why?
|
Clinical Laboratory Techniques | 1 | 2003 | 746 | 0.040 |
Why?
|
Depression | 1 | 2017 | 8230 | 0.040 |
Why?
|
Fatty Acids | 1 | 2005 | 1805 | 0.040 |
Why?
|
Feces | 1 | 2024 | 1503 | 0.040 |
Why?
|
Automation | 1 | 2020 | 585 | 0.040 |
Why?
|
North Carolina | 1 | 2018 | 329 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2023 | 1707 | 0.040 |
Why?
|
Cell Line, Transformed | 1 | 1999 | 858 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 817 | 0.040 |
Why?
|
Transcription, Genetic | 2 | 1992 | 7600 | 0.040 |
Why?
|
Saliva | 1 | 2022 | 852 | 0.040 |
Why?
|
Doxorubicin | 1 | 2024 | 2226 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2023 | 1194 | 0.030 |
Why?
|
Pain | 2 | 2022 | 5090 | 0.030 |
Why?
|
COS Cells | 1 | 1999 | 1135 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4249 | 0.030 |
Why?
|
Hepacivirus | 1 | 2024 | 1343 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2022 | 1239 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3501 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2003 | 2863 | 0.030 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2017 | 182 | 0.030 |
Why?
|
Cadherins | 1 | 2001 | 900 | 0.030 |
Why?
|
DNA Glycosylases | 1 | 2017 | 125 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2020 | 1072 | 0.030 |
Why?
|
Motivation | 2 | 2019 | 2019 | 0.030 |
Why?
|
Anorexia | 1 | 2016 | 153 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2022 | 1060 | 0.030 |
Why?
|
Nuclear Proteins | 4 | 2017 | 5791 | 0.030 |
Why?
|
Microsatellite Repeats | 2 | 2009 | 784 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2021 | 1117 | 0.030 |
Why?
|
Pancreas | 1 | 2022 | 1699 | 0.030 |
Why?
|
Postprandial Period | 1 | 2017 | 320 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2001 | 1322 | 0.030 |
Why?
|
Blotting, Northern | 1 | 1997 | 1546 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 1642 | 0.030 |
Why?
|
Europe | 1 | 2002 | 3430 | 0.030 |
Why?
|
Morbidity | 1 | 2020 | 1753 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 2020 | 723 | 0.030 |
Why?
|
Penetrance | 1 | 2017 | 388 | 0.030 |
Why?
|
Patient Preference | 1 | 2022 | 947 | 0.030 |
Why?
|
Nutritive Value | 1 | 2018 | 350 | 0.030 |
Why?
|
Chickens | 1 | 1997 | 842 | 0.030 |
Why?
|
Epidemiologic Methods | 2 | 2010 | 1325 | 0.030 |
Why?
|
DNA | 2 | 2024 | 7193 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1950 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2017 | 637 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 2001 | 1610 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1999 | 2743 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2353 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5889 | 0.030 |
Why?
|
Program Development | 1 | 2020 | 1297 | 0.030 |
Why?
|
Food, Fortified | 1 | 2015 | 189 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2001 | 3089 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1790 | 0.030 |
Why?
|
Demography | 1 | 2019 | 1641 | 0.030 |
Why?
|
Hydrocortisone | 1 | 2022 | 1832 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2015 | 544 | 0.030 |
Why?
|
Gene Expression | 2 | 2014 | 7582 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2021 | 2627 | 0.030 |
Why?
|
Leisure Activities | 1 | 2015 | 310 | 0.030 |
Why?
|
Leukocytes | 1 | 2022 | 2030 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2017 | 591 | 0.030 |
Why?
|
DNA, Complementary | 1 | 1997 | 1984 | 0.030 |
Why?
|
Life Expectancy | 1 | 2020 | 1248 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 702 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 903 | 0.030 |
Why?
|
Infant | 3 | 2023 | 36427 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 3722 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2108 | 0.030 |
Why?
|
Glioblastoma | 1 | 2008 | 3458 | 0.030 |
Why?
|
Mice | 6 | 2024 | 81839 | 0.030 |
Why?
|
Palliative Care | 2 | 2014 | 3639 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2016 | 658 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 753 | 0.030 |
Why?
|
Lost to Follow-Up | 1 | 2013 | 124 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2018 | 811 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2028 | 0.030 |
Why?
|
Macrophages | 2 | 2021 | 5776 | 0.030 |
Why?
|
Pancreatectomy | 1 | 2017 | 825 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2008 | 2898 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2005 | 3477 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2023 | 12775 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 2206 | 0.030 |
Why?
|
Organ Size | 1 | 2017 | 2260 | 0.020 |
Why?
|
Lymphocyte Activation | 2 | 2016 | 5503 | 0.020 |
Why?
|
Signal Transduction | 5 | 2014 | 23605 | 0.020 |
Why?
|
Lymph Node Excision | 2 | 2009 | 1262 | 0.020 |
Why?
|
Program Evaluation | 1 | 2020 | 2502 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2002 | 6309 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2844 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2019 | 2741 | 0.020 |
Why?
|
Colonoscopy | 1 | 2020 | 1408 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2016 | 1865 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2013 | 4342 | 0.020 |
Why?
|
Regression Analysis | 2 | 2012 | 6324 | 0.020 |
Why?
|
Trans-Activators | 1 | 2001 | 2849 | 0.020 |
Why?
|
Minnesota | 1 | 2011 | 339 | 0.020 |
Why?
|
Hydroxyestrones | 1 | 2010 | 17 | 0.020 |
Why?
|
Neoplasm Transplantation | 2 | 2011 | 2010 | 0.020 |
Why?
|
Eating | 1 | 2018 | 1538 | 0.020 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 385 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 14066 | 0.020 |
Why?
|
Patient Participation | 1 | 2020 | 1447 | 0.020 |
Why?
|
Internet | 1 | 2023 | 3107 | 0.020 |
Why?
|
RNA Probes | 1 | 1990 | 110 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 2022 | 2594 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 1999 | 4617 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 658 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2020 | 2006 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2016 | 640 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2039 | 0.020 |
Why?
|
Genomic Library | 1 | 1990 | 189 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2012 | 398 | 0.020 |
Why?
|
Causality | 1 | 2016 | 1247 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5531 | 0.020 |
Why?
|
Viral Proteins | 1 | 2017 | 1801 | 0.020 |
Why?
|
Puerto Rico | 1 | 2011 | 380 | 0.020 |
Why?
|
Skin | 1 | 2023 | 4482 | 0.020 |
Why?
|
Restriction Mapping | 1 | 1990 | 848 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2017 | 9601 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2005 | 4527 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 771 | 0.020 |
Why?
|
Rhabdomyosarcoma | 1 | 1992 | 354 | 0.020 |
Why?
|
Stroke | 1 | 2012 | 9748 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1750 | 0.020 |
Why?
|
Blotting, Western | 1 | 1997 | 5020 | 0.020 |
Why?
|
Phosphorylation | 2 | 2010 | 8292 | 0.020 |
Why?
|
Caenorhabditis elegans | 1 | 1999 | 1476 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 559 | 0.020 |
Why?
|
Epidemiologic Research Design | 1 | 2013 | 368 | 0.020 |
Why?
|
DNA Probes | 1 | 1990 | 541 | 0.020 |
Why?
|
Gene Deletion | 1 | 1997 | 2667 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 792 | 0.020 |
Why?
|
Spermatogenesis | 1 | 1990 | 259 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1990 | 1056 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2003 | 3530 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1068 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2048 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2017 | 6208 | 0.020 |
Why?
|
Medical History Taking | 1 | 2012 | 779 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1992 | 1242 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 130 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2611 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2008 | 126 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2689 | 0.020 |
Why?
|
Calcium Channels, T-Type | 1 | 2008 | 28 | 0.020 |
Why?
|
Physician's Role | 1 | 2015 | 925 | 0.020 |
Why?
|
Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 58 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7843 | 0.020 |
Why?
|
Seasons | 1 | 2013 | 1522 | 0.020 |
Why?
|
Sex Distribution | 1 | 2013 | 2270 | 0.020 |
Why?
|
Introns | 1 | 1990 | 965 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5873 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2018 | 1657 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2021 | 26381 | 0.020 |
Why?
|
Epigenesis, Genetic | 2 | 2012 | 3818 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 1167 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 455 | 0.020 |
Why?
|
Immunotherapy | 1 | 2003 | 4746 | 0.020 |
Why?
|
DNA Primers | 1 | 2011 | 2824 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2008 | 229 | 0.020 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 178 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3690 | 0.020 |
Why?
|
Wnt Proteins | 1 | 2011 | 721 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1602 | 0.020 |
Why?
|
Patient Care Team | 1 | 2018 | 2517 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2865 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1366 | 0.020 |
Why?
|
History, 21st Century | 1 | 2013 | 1574 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 713 | 0.020 |
Why?
|
Nerve Tissue Proteins | 2 | 2010 | 4399 | 0.020 |
Why?
|
Postoperative Care | 1 | 2013 | 1475 | 0.020 |
Why?
|
Patient Readmission | 1 | 2020 | 3283 | 0.020 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2006 | 46 | 0.020 |
Why?
|
Medication Adherence | 1 | 2018 | 2190 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4249 | 0.020 |
Why?
|
Species Specificity | 1 | 1990 | 2406 | 0.020 |
Why?
|
Alleles | 1 | 1997 | 6892 | 0.020 |
Why?
|
Child | 3 | 2021 | 80573 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2013 | 1512 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2009 | 1605 | 0.020 |
Why?
|
Organ Specificity | 1 | 1990 | 1966 | 0.020 |
Why?
|
Taxoids | 1 | 2009 | 665 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3733 | 0.020 |
Why?
|
RNA Stability | 1 | 2007 | 319 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3610 | 0.020 |
Why?
|
Self Administration | 1 | 2006 | 386 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 683 | 0.010 |
Why?
|
Child, Preschool | 2 | 2021 | 42511 | 0.010 |
Why?
|
Down-Regulation | 1 | 2012 | 2927 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2020 | 18967 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2006 | 6493 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12976 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2008 | 1836 | 0.010 |
Why?
|
Mortality | 1 | 2015 | 2911 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5510 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2390 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14747 | 0.010 |
Why?
|
Remission Induction | 1 | 2008 | 2413 | 0.010 |
Why?
|
Telemedicine | 1 | 2020 | 3108 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3424 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3796 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4565 | 0.010 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 1138 | 0.010 |
Why?
|
Desmogleins | 1 | 2001 | 4 | 0.010 |
Why?
|
Radiography | 1 | 2012 | 6943 | 0.010 |
Why?
|
alpha Catenin | 1 | 2001 | 37 | 0.010 |
Why?
|
Genetic Markers | 1 | 2007 | 2603 | 0.010 |
Why?
|
Chronic Disease | 1 | 2016 | 9354 | 0.010 |
Why?
|
Desmoplakins | 1 | 2001 | 64 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 4780 | 0.010 |
Why?
|
Boston | 1 | 2013 | 9335 | 0.010 |
Why?
|
Cell Aggregation | 1 | 2001 | 238 | 0.010 |
Why?
|
Heterozygote | 1 | 2007 | 2796 | 0.010 |
Why?
|
Drug Combinations | 1 | 2006 | 2076 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2008 | 2057 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 2001 | 6102 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 16040 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2010 | 3140 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15882 | 0.010 |
Why?
|
Primary Health Care | 1 | 2015 | 4736 | 0.010 |
Why?
|
Postmenopause | 1 | 2006 | 2517 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2001 | 1494 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2014 | 4863 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3537 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9508 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 11906 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 17071 | 0.010 |
Why?
|
Rats | 1 | 1990 | 23717 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 3436 | 0.010 |
Why?
|
Massachusetts | 1 | 2007 | 8882 | 0.010 |
Why?
|
Hospitalization | 1 | 2014 | 10811 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9445 | 0.010 |
Why?
|
Transfection | 1 | 2001 | 5739 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2006 | 4910 | 0.010 |
Why?
|
Receptors, Interleukin-1 | 1 | 1992 | 260 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2001 | 2815 | 0.010 |
Why?
|
Clinical Competence | 1 | 2007 | 4859 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15808 | 0.010 |
Why?
|
Feedback | 1 | 1992 | 796 | 0.000 |
Why?
|
Protein Biosynthesis | 1 | 1992 | 2091 | 0.000 |
Why?
|
Cell Division | 1 | 1992 | 4466 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1992 | 6215 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 36548 | 0.000 |
Why?
|